Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia

Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in acute myeloid leukemia (AML). Previously we demonstrated that AML patients with higher miR-29b expression had better response to the hypomethylating agent decitabine. Ther...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mims, Alice, Walker, Alison R., Huang, Xiaomeng, Sun, Jin, Wang, Hongyan, Santhanam, Ramasamy, Dorrance, Adrienne M., Walker, Chris, Hoellerbauer, Pia, Tarighat, Somayeh S., Chan, Kenneth K., Klisovic, Rebecca B., Perrotti, Danilo, Caligiuri, Michael A., Byrd, John C., Chen, Ching-Shih, Lee, L. James, Jacob, Samson, Mrózek, Krzysztof, Bloomfield, Clara D., Blum, William, Garzon, Ramiro, Schwind, Sebastian, Marcucci, Guido
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3764604/
https://ncbi.nlm.nih.gov/pubmed/23178755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.342
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares